Dr Stacey Richardson Dean Thompson Professor Steven Clifford Dr Rebecca Hill
| ARF suppression by MYC but not MYCN confers increased malignancy of aggressive pediatric brain tumors | 2023 |
|
Dr Jack Goddard Jemma Castle Emily Southworth Anya Fletcher Dr Stephen Crosier et al. | Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification | 2023 |
|
Dr Stacey Richardson Professor Steven Clifford
| Disease-associated KBTBD4 mutations in medulloblastoma elicit neomorphic ubiquitylation activity to promote CoREST degradation | 2022 |
|
Dr Stacey Richardson Dr Rebecca Hill Professor Steven Clifford
| Dormant SOX9-Positive Cells Facilitate MYC-Driven Recurrence of Medulloblastoma | 2022 |
|
Dr Stacey Richardson Dr Rebecca Hill Dr Christopher Kui Dr Janet Lindsey Dr Yura Grabovska et al. | Emergence and maintenance of actionable genetic drivers at medulloblastoma relapse | 2022 |
|
Dr Jack Goddard Jemma Castle Emily Southworth Anya Fletcher Dr Stephen Crosier et al. | MEDB-71. Molecular characterisation of Group 4 medulloblastoma improves risk-stratification and its biological understanding | 2022 |
|
Dr Daniel Williamson Dr Ed Schwalbe Dr Debbie Hicks Dr Janet Lindsey Dr Stephen Crosier et al. | Medulloblastoma group 3 and 4 tumors comprise a clinically and biologically significant expression continuum reflecting human cerebellar development | 2022 |
|
Dr Debbie Hicks Dr Reza Rafiee Dr Ed Schwalbe Dr Christopher Howell Dr Janet Lindsey et al. | The molecular landscape and associated clinical experience in infant medulloblastoma: prognostic significance of second-generation subtypes | 2021 |
|
Dr Rebecca Hill Dr Stacey Richardson Dr Ed Schwalbe Dr Debbie Hicks Dr Janet Lindsey et al. | Time, pattern, and outcome of medulloblastoma relapse and their association with tumour biology at diagnosis and therapy: a multicentre cohort study | 2020 |
|
Claire Schwab Sarra Ryan Dr Lucy Chilton Alannah Elliott James Murray et al. | EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications | 2016 |
|
Dr Sarra Ryan Elizabeth Matheson Dr Paul Sinclair Dr Matthew Bashton Claire Schwab et al. | The role of the RAS pathway in iAMP21-ALL | 2016 |
|
Professor Anthony Moorman Dr Amir Enshaei Claire Schwab Dr Lucy Chilton Alannah Elliott et al. | A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia | 2014 |
|
Claire Schwab Becca Andrews Dr Lucy Chilton Alannah Elliott Gerald Keil et al. | EBF1-PDGFRB Fusion in Paediatric Acute Lymphoblastic Leukaemia (ALL): Genetic Profile and Clinical Implications | 2014 |
|
Claire Schwab Becca Andrews Dr Lucy Chilton Alannah Elliott Dr Stacey Richardson et al. | SSBP2-CSF1R Is a Recurrent Fusion in B-Other Acute Lymphoblastic Leukaemia with Variable Clinical Outcome | 2014 |
|